We are live on ! Find out more
NTLA icon

Intellia Therapeutics

284 hedge funds and large institutions have $2.53B invested in Intellia Therapeutics in 2023 Q3 according to their latest regulatory filings, with 32 funds opening new positions, 119 increasing their positions, 67 reducing their positions, and 36 closing their positions.

New
Increased
Maintained
Reduced
Closed

78% more repeat investments, than reductions

Existing positions increased: 119 | Existing positions reduced: 67

63% more capital inflows, than outflows

Capital inflows: $197M | Capital outflows: $121M

1.75% more ownership

Funds ownership: 88.8% → 90.55% (+1.8%)

4% more call options, than puts

Call options by funds: $13.4M | Put options by funds: $12.8M

0% more funds holding in top 10

Funds holding in top 10: 6 → 6 (0)

2% less funds holding

Funds holding: 289 → 284 (-5)

11% less first-time investments, than exits

New positions opened: 32 | Existing positions closed: 36

Holders
284
Holders Change
-5
Holders Change %
-1.73%
% of All Funds
4.5%
Holding in Top 10
6
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.1%
New
32
Increased
119
Reduced
67
Closed
36
Calls
$13.4​M
Puts
$12.8​M
Net Calls
+$567​K
Net Calls Change
+$17​M

NTLA Hedge Fund Activity: Q3 2023 in Review

284 of the 6,315 institutional investors tracked by Wall St. Rank reported a position in Intellia Therapeutics (NTLA) for Q3 2023, worth a combined $2.53B — down 21% from $3.19B a quarter earlier.

Sellers outnumbered buyers: 36 funds closed out of NTLA and 32 opened new positions — a net loss of 4 holders — while 67 trimmed existing stakes and 119 added.

The largest buyer was Deep Track Capital, adding an estimated $45.2M. The largest seller was Charles Schwab, cutting an estimated $10.5M.

  • 284 institutional investors held Intellia Therapeutics (NTLA) as of Q3 2023, down from 289 in Q2 2023.
  • Funds reported $2.53B of Intellia Therapeutics stock for Q3 2023, down 21% quarter-over-quarter.
  • 32 funds opened new Intellia Therapeutics positions in Q3 2023 and 36 closed out, a net change of -4 holders.
  • The largest Intellia Therapeutics buyer in Q3 2023 was Deep Track Capital, an estimated $45.2M added.
  • The largest Intellia Therapeutics seller in Q3 2023 was Charles Schwab, an estimated $10.5M sold.

Based on aggregated 13F filings for Q3 2023.